-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This antibody can treat new coronavirus mutant infections |
The Yan Jinghua team from the Institute of Microbiology, Chinese Academy of Sciences, together with the Wang Chenhui team of Huazhong University of Science and Technology, the Xiao Junyu team of Peking University, the Wang Youchun team of China Food and Drug Control Institute, the Tan Wenjie team of China Center for Disease Control and Prevention, Shanghai Junshi Biomedical Technology Co.
, Ltd.
and other institutions, reported for the first time A blocking antibody that targets a variety of coronavirus invasion receptors ACE2; this antibody can effectively prevent and treat the new coronavirus and its mutants from infecting host cells and model animals, and has shown good results in non-human primates Security
.
Related research was published online in Nature-Communication on August 17th
For the first time, a blocking antibody targeting multiple coronavirus invasion receptors ACE2 is reported; this antibody can effectively prevent and treat the infection of host cells and model animals by the new coronavirus and its mutant strains, and is shown in non-human primates Good safety
The researchers first obtained a blocking monoclonal antibody h11B11 that targets the human ACE2 receptor through rapid screening and humanization of the antibody; the neutralization evaluation of pseudoviruses and true viruses of a variety of coronaviruses confirmed that the antibody h11B11 It has good inhibitory activity against SARS-CoV, new coronavirus and its mutant viruses
.
The study found that the combination of the antibody and the new crown therapeutic antibody CB6 developed by the Institute of Microbiology in the early stage can synergistically improve the neutralizing activity
.
CB6 monoclonal antibody is an antibody that targets the S protein RBD of the new crown pneumonia virus.
The researchers conducted further in vivo activity evaluation of the antibody through the hACE2 transgenic mouse infected with the new coronavirus model.
The results showed that compared with the placebo group, the lungs of the mice in the preventive administration group were basically undetectable; the treatment group was small.
The virus titer of mouse lungs was significantly reduced; the results of lung pathological section also showed that the pathological changes of the lungs of the mice in the prevention and treatment group were significantly improved
.
The researchers used the cynomolgus monkey model to evaluate the preclinical safety of the h11B11 antibody, proving that it has good in vivo safety
.
In order to clarify the mechanism of action and binding epitope of the h11B11 antibody, the researchers further analyzed the crystal structure of h11B11 and ACE2; this structure showed that the antibody mainly binds to the α-helix domain at the N-terminus of the ACE2 receptor; the antibody competes through epitopes and space.
Related paper information: https://doi.
https://doi.
org/10.
1038/s41467-021-25331-x https://doi.
org/10.
1038/s41467-021-25331-x